⚕ GalenOps field
←

SITE007-0021

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE007 (JPN) · Dr. Dubois
consented 2022-03-07

AEs
6
Serious
0
Dropout signal
–

Adverse events

moderate assessed

Grade 2 Hepatitis — outcome: RECOVERED/RESOLVED; onset 2022-07-06 (study day 101); relationship: Y

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-09 (study day 104); relationship: N

mild assessed

Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-10-28 (study day 215); relationship: N

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-20 (study day 268); relationship: N

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-03-18 (study day 356); relationship: N

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-09-01 (study day 889); relationship: Y

Data queries

No data queries.